Imperial College London
Portrait Picture

ProfessorAndreaRockall

Faculty of Medicine, Department of Surgery & Cancer

Clinical Chair in Radiology
 
 
 
//

Contact

 

a.rockall

 
 
//

Location

 

ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Taylor:2019:10.1016/S2213-2600(19)30090-6,
author = {Taylor, SA and Mallett, S and Ball, S and Beare, S and Bhatnagar, G and Bhowmik, A and Boavida, P and Bridgewater, J and Clarke, CS and Duggan, M and Ellis, S and Glynne-Jones, R and Goh, V and Groves, AM and Hameeduddin, A and Janes, SM and Johnston, EW and Koh, D-M and Lock, S and Miles, A and Morris, S and Morton, A and Navani, N and Oliver, A and O'Shaughnessy, T and Padhani, AR and Prezzi, D and Punwani, S and Quinn, L and Rafiee, H and Reczko, K and Rockall, AG and Russell, P and Sidhu, HS and Strickland, N and Tarver, K and Teague, J and Halligan, S and Streamline, investigators},
doi = {10.1016/S2213-2600(19)30090-6},
journal = {Lancet Respiratory Medicine},
pages = {523--532},
title = {Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: The prospective Streamline L trial.},
url = {http://dx.doi.org/10.1016/S2213-2600(19)30090-6},
volume = {7},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Whole-body magnetic resonance imaging (WB-MRI) could be an alternative to multi-modality staging of non-small-cell lung cancer (NSCLC), but its diagnostic accuracy, effect on staging times, number of tests needed, cost, and effect on treatment decisions are unknown. We aimed to prospectively compare the diagnostic accuracy and efficiency of WB-MRI-based staging pathways with standard pathways in NSCLC. METHODS: The Streamline L trial was a prospective, multicentre trial done in 16 hospitals in England. Eligible patients were 18 years or older, with newly diagnosed NSCLC that was potentially radically treatable on diagnostic chest CT (defined as stage IIIb or less). Exclusion criteria were severe systemic disease, pregnancy, contraindications to MRI, or histologies other than NSCLC. Patients underwent WB-MRI, the result of which was withheld until standard staging investigations were complete and the first treatment decision made. The multidisciplinary team recorded its treatment decision based on standard investigations, then on the WB-MRI staging pathway (WB-MRI plus additional tests generated), and finally on all tests. The primary outcome was difference in per-patient sensitivity for metastases between standard and WB-MRI staging pathways against a consensus reference standard at 12 months, in the per-protocol population. Secondary outcomes were difference in per-patient specificity for metastatic disease detection between standard and WB-MRI staging pathways, differences in treatment decisions, staging efficiency (time taken, test number, and costs) and per-organ sensitivity and specificity for metastases and per-patient agreement for local T and N stage. This trial is registered with the International Standard Randomised Controlled Trial registry, number ISRCTN50436483, and is complete. FINDINGS: Between Feb 26, 2013, and Sept 5, 2016, 976 patients were screened for eligibility. 353 patients were recruited, 187 of whom completed the trial; 52 (28%)
AU  - Taylor,SA
AU  - Mallett,S
AU  - Ball,S
AU  - Beare,S
AU  - Bhatnagar,G
AU  - Bhowmik,A
AU  - Boavida,P
AU  - Bridgewater,J
AU  - Clarke,CS
AU  - Duggan,M
AU  - Ellis,S
AU  - Glynne-Jones,R
AU  - Goh,V
AU  - Groves,AM
AU  - Hameeduddin,A
AU  - Janes,SM
AU  - Johnston,EW
AU  - Koh,D-M
AU  - Lock,S
AU  - Miles,A
AU  - Morris,S
AU  - Morton,A
AU  - Navani,N
AU  - Oliver,A
AU  - O'Shaughnessy,T
AU  - Padhani,AR
AU  - Prezzi,D
AU  - Punwani,S
AU  - Quinn,L
AU  - Rafiee,H
AU  - Reczko,K
AU  - Rockall,AG
AU  - Russell,P
AU  - Sidhu,HS
AU  - Strickland,N
AU  - Tarver,K
AU  - Teague,J
AU  - Halligan,S
AU  - Streamline,investigators
DO  - 10.1016/S2213-2600(19)30090-6
EP  - 532
PY  - 2019///
SN  - 2213-2600
SP  - 523
TI  - Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: The prospective Streamline L trial.
T2  - Lancet Respiratory Medicine
UR  - http://dx.doi.org/10.1016/S2213-2600(19)30090-6
UR  - https://www.ncbi.nlm.nih.gov/pubmed/31080129
UR  - http://hdl.handle.net/10044/1/70773
VL  - 7
ER  -
Download